A research group led by Dr. Daisuke MURAOKA, Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Dr. MOI MENG LING, School of International Health, Graduate School of Medicine, the University of Tokyo, Dr. Kazunari AKIYOSHI, Department of Immunology, Graduate School of Medicine, Kyoto University, Dr. Hiroaki IKEDA, Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, and Dr. Naozumi Harada, United Immunity, Co., Ltd.,, have demonstrated that the selective delivery of PNG to medullary macrophages depends on its binding to the C-type lectin SIGN-R1.
This induction of specific CD8-positive killer T cells that respond rapidly to viral infection, even at low frequencies, is critical for vaccine efficacy and can be achieved by targeting SIGN-R1⁺ myeloid macrophages.
In this study, our T-cell receptor (TCR) Repertoire Analysis technology was used as a method to identify clonal differences in induced CD8-positive killer T cells.

The results of this research are published in a news release on the following website.
Tokyo University: Research publication on PNG based infectious disease vaccine development

Kyoto University: 我が国独自のナノ粒子性薬剤送達システムを用いた次世代ワクチンの新型コロナウイルスに対する優れたキラーT細胞誘導と感染防御性能を動物モデルで実証―将来の感染症ワクチン開発への幅広い応用の可能性―　(Japanese)

Nagasaki University: T細胞誘導と感染防御性能を動物モデルで実証　(Japanese)

Aichi Cancer Center: T細胞誘導と感染防御性能を動物モデルで実証　(Japanese)

United Immunity Co., Ltd.: A Next-Generation COVID-19 Vaccine Using Myeloid Targeting PlatformTM Shows Superior Killer T Cell Induction and Infection Protection Properties in a Preclinical Animal Model

npj vaccines
Low-frequency CD8⁺ T cells induced by SIGN-R1⁺ macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice

To "Publications" page